Product & Industry News
Drug Discovery World
UK government advises drug companies to stockpile in case of Brexit disruption

UK government advises drug companies to stockpile in case of Brexit disruption

4 August 2020
Image: Joshua Coleman

According to the Department of Health and Social Care (DHSC), pharmaceutical companies should stockpile six weeks' worth of goods "to help ensure the continuity of supply of medical goods into and out of the UK".

In a letter to the industry Steve Oldfield, Chief Commercial Officer, acknowledges the impact of COVID-19 on the sector and the strain this has placed on supply chains. With no intention of a Brexit extension beyond 31 December, the government is aware that leaving without a deal may cause supply chain disruption. 

The communication outlines that the focus should now be on mitigating any potential disruption to supply into the UK across all categories of medical supplies, including, medicines, medical devices and clinical consumables, clinical trials supplies, products of human origin (blood and transplant items), and vaccines and countermeasures. 

The government is asking suppliers to put in place “flexible mitigation and readiness plans in preparation for new border and customs procedures” as well as advising that all scenarios must be planned for such as reduced traffics flow at short Channel crossings like Dover and Calais. With a significant percentage of medical supplies coming from or via the EU, the government says that a key priority must be to “maintain replenishment rates at necessary levels by securing capacity to reroute freight away from the short straits potential disruption points”. As such it is urging businesses to review current logistics with a view to avoiding these routes.

Acknowledging that global supply chains have been under huge amounts of strain due to COVID-19, the letter encourages “companies to make stockpiling a key part of contingency plans, and ask industry, where possible, to stockpile to a target level of 6 weeks’ total stock on UK soil”.

More on this subject...
The apocalyptic horsemen of the pharma industry cartoon illustration

The Apocalyptic Horsemen of Drug Discovery and Development READ MORE

A roadmap for achieving self-sustainability of academic high throughput screening core facilities READ MORE

Editing the Human Genome: Role in Functional Genomics and Translational Medicine READ MORE

New Tools Increase Accessibility to High Content Screening Assays READ MORE

The Application of iPS Cells and Differentiated Neuronal Cells To Advance Drug Discovery Main Image

The Application of iPS Cells and Differentiated Neuronal Cells To Advance Drug Discovery READ MORE

In Vivo Imaging In Drug Development: Gamma Scintigraphy READ MORE

Innovate while derisking drug development - yes we can!

Innovate While Derisking Drug Development: Yes We Can! READ MORE

Stem cells, cell-based assays and the world of small molecules

Stem Cells: Cell-Based Assays and the World of Small Molecules READ MORE

Pharmaceutical and biomedical research likely to use 1 billion dollars worth of microfluidics devices by 2016

Pharmaceutical & biomedical research likely to use $1 billion worth of microfluidics devices by 2016 READ MORE

Asian innovation

Asian Innovation: A Unique Opportunity For The Pharmaceutical Industry READ MORE